DBV Technologies S.A. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DBVT Nasdaq 2836 www.dbv-technologies.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for DBV Technologies S.A.

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - Jun 30th, 2025 9:14 am
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - Jun 26th, 2025 9:00 am
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old - Jun 25th, 2025 2:15 pm
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading - Jun 25th, 2025 9:04 am
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - Jun 24th, 2025 9:08 am
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading - Jun 23rd, 2025 9:14 am
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - Jun 17th, 2025 9:03 am
DBV Technologies to Participate in Upcoming EAACI Congress 2025 - Jun 12th, 2025 2:05 pm
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting - Jun 11th, 2025 2:30 pm
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025 - Jun 4th, 2025 2:32 pm
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document - Jun 3rd, 2025 2:30 pm
Combined General Meeting of June 11, 2025 - May 15th, 2025 2:30 pm
Information regarding the total number of voting rights and  total number of shares of the Company as of April 30, 2025 - May 6th, 2025 2:30 pm
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference - May 5th, 2025 2:30 pm
DBV Technologies Reports First Quarter 2025 Financial Results - Apr 30th, 2025 2:00 pm
Why DBV Technologies S.A. (DBVT) is Surging in 2025 - Apr 30th, 2025 4:25 am
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - Apr 11th, 2025 2:30 pm
Novo gains Lexicon obesity drug; CRISPR COO to step down - Mar 28th, 2025 5:01 am
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved - Mar 27th, 2025 8:30 pm
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results... - Mar 24th, 2025 12:30 am